Introduction:

some antiretrovirals affect the lipid profile in human immunodeficiency virus patients increasing their cardiovascular risk. Integrase inhibitors generate little lipid alteration. The present study evaluated the best available evidence about changes in the lipid profile in human immunodeficiency virus patients who had switch from different antiretroviral therapies to schemes with integrase inhibitors.

Methods:

a systematic review with meta-analytic intention was carried out. From the question "How does antiretroviral schemes with integrase inhibitors impact in lipid profile in human immunodeficiency virus patients compared to antiretroviral schemes without integrase inhibitors?" an evidence search was done. Articles from experimental and observational studies were included and the quality was evaluated. An analysis by integrase inhibitor and lipid parameters was performed.

Results:

17 relevant studies were identified and 2 878 patients were included in the quantitative synthesis. According to evidence, integrase inhibitors had a better lipid profile compared to other antiretrovirals. Dolutegravir had a better metabolic profile when it was compared with protease inhibitors. Raltegravir had a better lipid profile when it was compared to non-nucleoside analog reverse transcriptase inhibitors.

Conclusions:

integrase inhibitors are a relevant factor for cardiovascular risk control in patients with human immunodeficiency virus.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )